Bleeding and thrombosis in cirrhotic patients: What really matters?

Digestive and Liver Disease

Volumn 44, Issue 4, 2012, Pages 275-279

  Ferro, Domenico ^a   Angelico, Francesco ^a   Caldwell, Stephen H ^b   Violi, Francesco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Bleeding; Coagulation; Liver cirrhosis; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 8; D DIMER; TISSUE PLASMINOGEN ACTIVATOR;

BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; CENTRAL VENOUS CATHETERIZATION; ESOPHAGUS HEMORRHAGE; ESOPHAGUS VARICES BLEEDING; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LAPAROSCOPY; LIVER BIOPSY; LIVER CIRRHOSIS; NONALCOHOLIC FATTY LIVER; PARACENTESIS; PEPTIC ULCER BLEEDING; PERCUTANEOUS BIOPSY; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; SCORING SYSTEM; THORACOCENTESIS; VALSALVA MANEUVER;

BIOPSY; BLOOD COAGULATION DISORDERS; CATHETERIZATION, CENTRAL VENOUS; CEREBRAL HEMORRHAGE; GASTROINTESTINAL HEMORRHAGE; HUMANS; LIVER; LIVER CIRRHOSIS; PARACENTESIS; PORTAL VEIN; VENOUS THROMBOSIS;

EID: 84857641700     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2011.10.016     Document Type: Review

References (65)

1. Wion K., Kelly D., Summerfield J.A., et al. Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature 1985, 317:726-729.
2. Tripodi A., Mannucci P.M. The coagulopathy of chronic liver disease. N Engl J Med 2011, 365:147-156.
3. Tripodi A., Primignani M., Chantarangkul V., et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009, 137:2105-2111.
4. D'Angelo A., Vigano-D'Angelo S., Esmon C.T., et al. Acquired deficiencies of protein S. Protein S activity during oral anticoagulation, in liver disease, and in disseminated intravascular coagulation. J Clin Invest 1988, 81:1445-1454.
5. Violi F., Ferro D., Basili S., et al. Association between low-grade disseminated intravascular coagulation and endotoxemia in patients with liver cirrhosis. Gastroenterology 1995, 109:531-539.
6. Violi F., Ferro D., Basili S., et al. Ongoing prothrombotic state in the portal circulation of cirrhotic patients. Thromb Haemost 1997, 77:44-47.
7. Tripodi A., Primignani M., Lemma L., et al. Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology 2010, 52:249-255.
8. O'Donnell J., Mumford A.D., Manning R.A., et al. Marked elevation of thrombin generation in patients with elevated FVIII: C and venous thromboembolism. Br J Haematol 2001, 115:687-691.
9. Hollestelle M.J., Geertzen H.G., Straatsburg I.H., et al. Factor VIII expression in liver disease. Thromb Haemost 2004, 91:267-275.
10. Ferro D., Quintarelli C., Lattuada A., et al. High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. Hepatology 1996, 23:1377-1383.
11. Saliola M., Lorenzet R., Ferro D., et al. Enhanced expression of monocyte tissue factor in patients with liver cirrhosis. Gut 1998, 43:428-432.
12. Farmer A.D., Saadeddin A., Holt C.E., et al. Portal vein thrombosis in the district general hospital: management and clinical outcomes. Eur J Gastroenterol Hepatol 2009, 21:517-521.
13. Sharara A.I., Rockey D.C. Gastroesophageal variceal hemorrhage. N Engl J Med 2001, 345:669-680.
14. Hou M.C., Lin H.C., Liu T.T., et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology 2004, 39:746-753.
15. Prediction of the first variceal bleeding in the individual patient with cirrhosis of the liver and esophageal varices. N Engl J Med 1988, 319:983-989. North Italian Endoscopic Club for the Study of Treatment of Varices.
16. Merkel C., Zoli M., Siringo S., et al. Prognostic indicators of risk for first variceal bleeding in cirrhosis: a multicenter study in 711 patients to validate and improve the North Italian Endoscopic Club (NIEC) index. Am J Gastroenterol 2000, 95:2915-2920.
17. Liao W.C., Hou M.C., Chang C.J., et al. Potential precipitating factors of esophageal variceal bleeding: a case-control study. Am J Gastroenterol 2011, 106:96-103.
18. Vieira da Rocha E.C., D'Amico E.A., Caldwell S.H., et al. A prospective study of conventional and expanded coagulation indices in predicting ulcer bleeding after variceal band ligation. Clin Gastroenterol Hepatol 2009, 7:988-993.
19. Violi F., Ferro D., Basili S., et al. Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis. Hepatology 1992, 15:672-676.
20. Huang H.-H., Lin H.-H., Shih Y.-L., et al. Spontaneous intracranial hemorrhage in cirrhotic patients. Clin Neurol Neurosurg 2008, 110:253-258.
21. Lee H.-J., Hinrichs C.R. Is coagulopathic liver disease a factor in spontaneous cerebral hemorrhage?. J Comp Assist Tomogr 2002, 26:69-72.
22. Grønbaek H., Johnsen S.P., Jepsen P., et al. Liver cirrhosis, other liver diseases, and risk of hospitalisation for intracerebral haemorrhage: a Danish population-based case-control study. BMC Gastroenterol 2008, 8:16.
23. Peng G.S., Yin S.J., Cheng C.A., et al. Increased risk of cerebral hemorrhage in Chinese male heavy drinkers with mild liver disorder. Cerebrovasc Dis 2007, 23:309-314.
24. Del Ben M., Caporale A., Feole K., et al. Intracranial hemorrage due to brain metastases in an Italian HCV patient with hepatocellular carcinoma. J Exp Clin Cancer Res 2003, 22:641-644.
25. Hsieh M.-J., Lu C.-H., Tsai N.-W., et al. Prediction, clinical characteristics and prognosis of intracerebral hemorrhage in hepatocellular carcinoma patients with intracerebral metastasis. J Clin Neurosci 2009, 16:394-398.
26. Maha A.S., Knauer M., Gregory P.B. Bleeding after liver biopsy. West Med J 1981, 134:11-14.
27. Segal J.B., Dzik W.H. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005, 54:1404-1406.
28. McVay P.A., Toy P.T. Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities. Am J Clin Pathol 1990, 94:747-753.
29. Caldwell S., Northup P.G. Bleeding complication with liver biopsy: is it predictable?. Clin Gastroenterol Hepatol 2010, 8:826-829.
30. Seeff L.B., Everson G.T., Morgan T.R., et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol 2010, 8:877-883.
31. Foster P.F., Moore L.R., Sankary H.N. Central venous catheterization in patients with coagulopathy. Arch Surg 1992, 127:273-275.
32. Fisher N.C., Mutimer D.J. Central venous cannulation in patients with liver disease and coagulopathy. A prospective audit. Intensive Care Med 1999, 25:481-485.
33. McGibbon A., Chen G.I., Peltekian K.M., et al. An evidence-based manual for abdominal paracentesis. Dig Dis Sci 2007, 52:3307-3315.
34. De Gottardi A., Thevenot T., Spahr L., et al. Risk of complications after abdominal paracentesis in cirrhotic patients: a prospective study. Clin Gastroenterol Hepatol 2009, 7:906-909.
35. McVay P., Toy P. Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion 1991, 31:164-171.
36. Pache I., Bilodeau M. Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease. Aliment Pharmacol Ther 2005, 21:525-529.
37. Argo C.K., Balogun R.A. Blood products, volume control, and renal support in the coagulopathy of liver disease. Clin Liver Dis 2009, 13:73-85.
38. Janssen H.L., Wijnhoud A., Haagsma E.B., et al. Extrahepatic portal vein thrombosis: aetiology and determinants of survival. Gut 2001, 49:720-724.
39. Ogren M., Bergqvist D., Bjorck M., et al. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol 2006, 12:2115-2119.
40. Francoz C., Belghiti J., Vilgrain V., et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005, 54:691-697.
41. Amitrano L., Brancaccio V., Guardascione M.A., et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology 2000, 31:345-348.
42. Fimognari F.L., De Santis A., Piccheri C., et al. Evaluation of D-Dimer and factor VIII in cirrhotic patients with asymptomatic portal venous thrombosis. J Lab Clin Med 2005, 146:238-243.
43. Gaiani S., Bolondi L., Li B.S., et al. Prevalence of spontaneous hepatofugal portal flow in liver cirrhosis. Clinical and endoscopic correlation in 228 patients. Gastroenterology 1991, 100:160-167.
44. Primignani M. Portal vein thrombosis, revisited. Dig Liver Dis 2010, 42:163-170.
45. Okuda K., Ohnishi K., Kimura K., et al. Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients. Gastroenterology 1985, 89:279-286.
46. Belli L., Romani F., Sansalone C.V., et al. Portal thrombosis in cirrhotics. A retrospective analysis. Ann Surg 1986, 203:286-291.
47. Orloff M.J., Orloff M.S., Orloff S.L., et al. Portal vein thrombosis in cirrhosis with variceal hemorrhage. Gastrointest Surg 1997, 1:123-130.
48. Sarfeh I.J. Portal vein thrombosis associated with cirrhosis: clinical importance. Arch Surg 1979, 114:902-905.
49. Nonami T., Yokoyama I., Iwatsuki S., et al. The incidence of portal vein thrombosis at liver transplantation. Hepatology 1992, 16:1195-1198.
50. Martinelli I., Primignani M., Aghemo A., et al. High levels of Factor VIII and risk of extra hepatic portal vein obstruction. J Hepatol 2009, 50:916-922.
51. Violi F., Ferro D., Quintarelli C., et al. Dilute aPTT prolongation by antiphospholipid antibodies in patients with liver cirrhosis. Thromb Haemostas 1990, 63:183-186.
52. Quintarelli C., Ferro D., Valesini G., et al. Prevalence of lupus anticoagulant in patients with cirrhosis: relationship with beta-2-glycoprotein I plasma levels. J Hepatol 1994, 21:1086-1109.
53. Violi F., Ferro D., Basili S., et al. Relation between lupus anticoagulant and splanchnic venous thrombosis in cirrhosis of the liver. Br Med J 1994, 309:239-240.
54. Mangia A., Margaglione M., Cascavilla I., et al. Anticardiolipin antibodies in patients with liver disease. Am J Gastroenterol 1999, 94:2983-2987.
55. Oksuzoglu G., Bayraktar Y., Arslan S., et al. Portal vein thrombosis in cirrhotics: related with anticardiolipin antibodies?. Hepatogastroenterology 2003, 50:1527-1530.
56. Romero G.M., Suarez G.E., Lopez L.D., et al. Antiphospholipid antibodies are related to portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2000, 31:237-240.
57. Northup P.G., McMahon M.M., Ruhl A.P., et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006, 101:1524-1528.
58. Gulley D., Teal E., Suvannasankha A., et al. Deep vein thrombosis and pulmonary embolism in cirrhosis patients. Dig Dis Sci 2008, 53:3012-3017.
59. Garcia-Fuster M.J., Abdilla N., Fabia M.J., et al. Venous thromboembolism and liver cirrhosis. Esp Enferm Dig 2008, 100:259-262.
60. Sogaard K.K., Horvath-Puho E., Gronbaek H., et al. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol 2009, 104:96-101.
61. Cervera A., Amaro S., Chamorro A. Oral anticoagulant-associated intracerebral hemorrhage. J Neurol 2011 July 5, [Epub ahead of print].
62. Tozzi Ciancarelli M.G., Di Massimo C., De Amicis D., et al. Moderate consumption of red wine and human platelet responsiveness. Thromb Res 2011, 128:124-129.
63. Violi F., Basili S., Raparelli V., et al. Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction?. J Hepatol 2011 June 28, [Epub ahead of print].
64. Romualdi E., Ageno W. Oral Xa inhibitors. Hematol Oncol Clin North Am 2010, 24:727-737.
65. Wallentin L., Yusuf S., Ezekowitz M.D., et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010, 376:975-998.